Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US based drug developer Alnylam Pharmaceuticals has concluded an open label, multi-center, dose escalation Phase I trial evaluating ALN-VSP as a treatment for advanced solid tumors with liver involvement.
Subscribe to our email newsletter
ALN-VSP is a systemically delivered RNAi therapeutic which includes two siRNAs intended to target two genes critical for the growth and development of cancer cells: vascular endothelial growth factor (VEGF) and kinesin spindle protein (KSP), also known as eglin 5 (Eg5).
In the trial, the patients were treated at doses ranging from 0.1 to 1.5 mg/kg.
Alnylam Clinical Research senior director Jared Gollob said the results of ALN-VSP Phase I trial demonstrated safety and tolerability of multiple doses of ALN-VSP in addition to evidence for anti-tumor activity and proof of RNAi mechanism from tissue biopsy samples.